Demand for specialized diagnostics is rising as healthcare systems manage a growing burden of chronic disease, and that demand sits at the heart of the laboratory developed tests market. Polaris Market Research reports a market value of USD 14.16 billion in 2025, a 2026 estimate of USD 15.19 billion, and a projected USD 26.97 billion by 2034, at a 7.4% CAGR from 2026 to 2034. This article looks at who is buying and building these tests, the testing models gaining traction, and the commercial hurdles laboratories must plan for.

Chronic Disease and Specialized Testing Needs

The rising prevalence of chronic diseases is a primary driver. An April 2026 OECD report cited by Polaris indicates that newly diagnosed cases of noncommunicable diseases may increase by 31% in OECD countries by 2050, and by 29% in EU countries. Testing is often needed at the start of treatment to diagnose disease and later to monitor progress, creating continued demand in cancer, diabetes, heart disease, and chronic respiratory conditions.

Because LDTs allow laboratories to run tests that no commercial product can deliver, this demand is expected to support specialized lab testing over the longer term. Molecular diagnostics innovations are also enabling detection of a wider range of biomarkers, which increases the need for tests tailored to particular diseases, patients, or clinical conditions.

Hospital Laboratories Lead End Use

By end use, hospital laboratories held a 40.21% share in 2025. Their position reflects direct integration with clinical care: hospital labs test admitted patients and often need specialized assays when conditions are complex or no commercial test exists. LDTs let them build methods that match local clinical needs and support timely diagnosis of complicated cases, which keeps hospital labs at the forefront of the industry worldwide.

Reference Laboratories Extend the Test Menu

Private and independent reference laboratories are projected to grow at a 7.8% CAGR. These laboratories perform specialty tests for hospitals, physicians, and other healthcare institutions, and their portfolios often include assays that require lab-specific expertise. LDTs help them develop tests for particular biomarkers or rarer diseases where no standard product exists, and as new biomarkers enter practice they can keep expanding their menus.

A real-world example is Mayo Clinic Laboratories' April 2026 report on advances in testing for Birt-Hogg-Dube syndrome, a rare inherited kidney cancer syndrome, where updated testing helped address gaps in genetic diagnosis.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/laboratory-developed-tests-market 

Testing Trends: Multiplex Panels and Sequencing

Laboratories are increasingly building assays that analyze several targets from a single patient sample. Multiplex testing is relevant when symptoms overlap across diseases or when multiple biomarkers must be assessed together, and it is gaining relevance in infectious disease testing, oncology, and genomics. Because laboratories can design panels around their own needs, the trend may shift demand toward testing panels rather than single-target tests.

At the same time, access to platforms for next-generation sequencing and digital PCR is helping laboratories identify genetic mutations that traditional techniques cannot evaluate, particularly where greater sensitivity or a more comprehensive view of genetic markers is required. These methods are expected to widen the range of tests laboratories can develop.

Reimbursement and Standardization Challenges

The main restraint is reimbursement uncertainty. Payers may judge the clinical usefulness of an LDT differently, especially when a test is new or addresses a special clinical condition, which makes it hard for laboratories to forecast the revenue a new test will generate. Prices also vary by testing company and healthcare setting.

In addition, different methodologies can make results harder to compare between laboratories, so consistent validation and quality control procedures are essential. Together, these factors create uncertainty around adoption, and Polaris notes that reimbursement and practice differences could pose challenges to the market.

Growth Opportunities

Emerging clinical areas such as genomics, infectious diseases, and rare diseases often need testing before commercial assays exist, and specialized laboratories can create assays for biomarkers with few alternatives. LDTs may also facilitate clinical adoption of new technologies while evidence and testing methods are still being developed. Regionally, Asia Pacific is projected to grow at an 8.6% CAGR, while the nutritional & metabolic disease application segment is projected to grow at an 8.2% CAGR, driven by expanding neonatal and genetic screening.

Key Players

Participants named in the report include 23andMe, Abbott Laboratories, ARUP Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Illumina, Inc., Laboratory Corporation of America Holdings (Labcorp), Mayo Clinic Laboratories, NeoGenomics Laboratories, Inc., QIAGEN N.V., Quanterix Corporation, Quest Diagnostics Incorporated, and Siemens Healthineers AG. In September 2026, Quest Diagnostics announced that U.S. Apple Health app users will be able to purchase a tailored laboratory test panel covering over 50 biomarkers directly through the app later this year.

Conclusion

The laboratory developed tests market is driven by chronic disease burden and demand for specialized diagnostics, with hospital laboratories leading end use and reference laboratories expanding the test menu. Multiplex panels and advanced sequencing are widening what laboratories can build, while reimbursement and standardization remain the key hurdles. Stakeholders that align assay development with clinical need and consistent quality processes will be best placed as the market moves toward USD 26.97 billion by 2034.

More Trending Latest Reports By Polaris Market Research:

Artificial Flowers Market

Direct Air Capture Systems Market

Laboratory Developed Tests Market

Automated Cell Culture Market

Electric Vehicle Charging Infrastructure Market

Surfactants Market

Human Platelet Lysate Market

Artificial Intelligence (Ai) In Pharmaceutical Market

Ferrous Sulfate Market